Health regulators in Switzerland have issued a precautionary recall for specific batches of Cinglan Filmtabletten, a medication used to manage complex endocrine disorders. The Federal Office of Public Health (BASG) announced that the recall is due to a reduced release of the active ingredient, which could potentially compromise the efficacy of the treatment.
The recall affects both the 30 mg and 60 mg dosages of the medication, which contains the active ingredient Cinacalcet. According to official notifications, the issue was identified during routine stability testing, leading to a recall that extends down to the pharmacy level to ensure patient safety.
For patients relying on Cinglan to regulate calcium and parathyroid hormone levels, any decrease in the drug’s bioavailability can be significant. As a physician, I recognize that medications for hyperparathyroidism require precise dosing to prevent bone loss and maintain mineral balance in the blood. When a drug does not release its active ingredient as intended, the patient may not receive the full therapeutic dose, potentially leading to a recurrence of symptoms or complications associated with uncontrolled hormone levels.
Identifying Affected Batches
The recall is not universal across all Cinglan products but is limited to specific lots manufactured by G.L. Pharma GmbH. Patients are urged to check their medication packaging immediately to observe if their prescription matches the affected batch numbers and expiration dates.
The specific details for the recalled medications are as follows:
| Dosage | Batch Number | PZN (Pharma-Zentralnummer) | Expiry Date |
|---|---|---|---|
| 60 mg | F11087 | 4968276 | 30.09.2027 |
| 30 mg | K01116 | 4968253 | 30.09.2027 |
If you possess a medication bottle matching these specifications, Consider contact your pharmacist or healthcare provider immediately. Do not abruptly stop taking your medication without professional guidance, as managing parathyroid function requires a controlled transition to a replacement batch.
Understanding Cinacalcet and Hyperparathyroidism
To understand why this recall is critical, It’s necessary to look at the role of the parathyroid glands. These modest glands in the neck regulate the body’s calcium levels by secreting parathyroid hormone (PTH). In cases of secondary hyperparathyroidism—often associated with chronic kidney disease—these glands become overactive, secreting excessive amounts of PTH.
When PTH levels are too high, the body begins to mobilize calcium from the bones into the bloodstream. This process, known as hypercalcemia, not only elevates blood calcium but also leads to the systemic demineralization of the skeleton. Over time, this weakens the bone structure, significantly increasing the risk of fractures and bone pain.
Cinacalcet belongs to a class of drugs known as calcimimetics. It works by increasing the sensitivity of the calcium-sensing receptors (CaSR) on the parathyroid gland. By “tricking” the gland into sensing more calcium than is actually present, Cinacalcet effectively suppresses the secretion of PTH, thereby lowering both PTH and calcium levels in the blood.
Pharmacologically, Cinacalcet has a bioavailability of approximately 25 percent and a relatively long half-life of up to 40 hours. Because of this gradual clearance, consistency in the active ingredient’s release is paramount to maintaining a steady state of the drug in the patient’s system.
What Which means for Patients
A “reduced active ingredient release” means that the tablet may not dissolve or release the Cinacalcet into the digestive tract at the rate required for absorption. For a patient with a parathyroid carcinoma or severe secondary hyperparathyroidism, this could result in a spike of PTH, potentially accelerating bone loss or causing symptoms of hypercalcemia, such as fatigue, nausea, or confusion.
The BASG’s decision to recall these batches at the pharmacy level is a proactive measure. By removing these specific lots from circulation, regulators aim to prevent any patient from starting or continuing a course of treatment with sub-potent medication.
Next Steps for Affected Individuals
If you find that your medication is part of the recall, the primary point of contact should be your dispensing pharmacy. They are equipped to handle the return of the defective batches and coordinate with G.L. Pharma GmbH for replacements.
Patients should be prepared to discuss the following with their doctor:
- Whether they have noticed a return of symptoms related to high calcium levels.
- The timeline for obtaining a replacement batch to avoid a gap in therapy.
- Whether additional blood tests for calcium and PTH levels are necessary to ensure their condition remains stable.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication.
The BASG continues to monitor the stability of pharmaceutical products in the Swiss market. Further updates regarding the Cinglan recall or additional affected batches will be posted through official government health channels as stability investigations conclude.
We invite you to share this information with others who may be taking this medication and to leave your comments or questions below.
